Strive, a Nasdaq-listed asset manager, purchased an additional 1,223 bitcoins at an average price of $81,734 each, spending about $100 million between October 14 and 16. This brings its total bitcoin holdings to 36,818 BTC, worth roughly $3 billion. The company is also preparing to raise $630 million through a preferred-stock offering expected to settle on October 20, which could fund further bitcoin acquisitions. Strive's strategy of using equity and preferred securities for funding sets it apart from competitors relying on traditional borrowing.
Strive's recent bitcoin purchase and planned cash raise provide context for readers. For those following cryptocurrency markets, here is Pluang's snapshot as of Oct 19, 2026 23:31 WIB: Of 50 major cryptocurrencies priced on Pluang, 41 rose and 8 fell today. Notable movers include SUSHI at Rp3.913 (+4.11%), BAT at Rp3.270 (+3.95%), and LTC at Rp1.080.951 (+3.82%).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
